ライフサイエンスコーパス: butyrate

1 y acids, including the clinically beneficial butyrate.

2 -derived Wnt-5a and the microbial metabolite butyrate.

3 ored after local administration of exogenous butyrate.

4 cular-weight (LMW) organic acids acetate and butyrate.

5 ropanediol, 1,3-butanediol, isopropanol, and butyrate.

6 the production of the short-chain fatty acid butyrate.

7 ing short-chain fatty acids (SCFAs), such as butyrate.

8 ly lower concentrations of tumor-suppressive butyrate (22.5 +/- 3.1 compared with 47.2 +/- 7.3 SEM um

9 Conversion of acetate into butyrate (24%) was the most prevalent interconversion by

10 chemical compounds (3C) consisting of sodium butyrate (a broad histone deacetylase inhibitor), UNC064

11 Notably, butyrate, a metabolite produced by the vancomycin-deplet

12 Unbiased screening identified butyrate, a prominent bacterial metabolite, as a potent

13 Butyrate absorption decreased in HS animals (P < 0.05) b

14 logenetic groups and key metabolites such as butyrate, acetate and propionate in response to a one un

15 The mechanism of butyrate action depended on the transcription factor Fox

16 These observations suggest that the butyrate activation of NHE2 would be a potential target

17 Bacteria-derived butyrate affects epithelial O2 consumption and results i

18 ted SCFAs (61:22:17, acetate, propionate and butyrate) after prolonged (24h) fermentation, suppressed

19 lization abolished the protective effects of butyrate against hepatic IR injury.

20 In vivo butyrate ameliorated allergen-induced airway and lung eo

21 e microbiota-generated intestinal metabolite butyrate, an important factor for host intestinal health

22 structurally related short-chain fatty acids butyrate and acetate, suppresses activation of the NLRP3

23 Fecal levels of butyrate and ammonia decreased during the GFD.

24 ate production was increased (P < 0.01), and butyrate and ammonia outputs and the acetate to propiona

25 mechanistic link between microbiota-derived butyrate and barrier restoration.

26 rthermore, known signaling regulators (e.g., butyrate and DAPT) produced measurable and predictable e

27 ria, particularly loss of those that produce butyrate and degrade oxalate, associates with perturbati

28 In particular, butyrate and FBA improved respiratory capacity and fatty

29 f the mitochondrial dynamic toward fusion by butyrate and FBA resulted in the improvement not only of

30 st 3 odorants (ethyl 2-methylbutyrate, ethyl butyrate and hexanoate).

31 depletion of the microbiota reduces colonic butyrate and HIF expression, both of which are restored

32 s a derivative of the short-chain fatty acid butyrate and is approved for treatment of urea cycle dis

33 In conclusion, butyrate and its more palatable synthetic derivative, FB

34 ucts of bacterial anaerobic metabolism, like butyrate and other short-chain fatty acids (SCFAs), indu

35 se in the circulating short-chain fatty acid butyrate and pain improvement following FMT.

36 Children with the highest levels of butyrate and propionate (>=95th percentile) in feces at

37 Short-chain fatty acids (SCFAs) butyrate and propionate are metabolites from dietary fib

38 In human and mouse B cells, butyrate and propionate decrease B cell Aicda and Prdm1

39 ike acetate, short chain fatty acids such as butyrate and propionate failed to prevent loss of cell v

40 tic IR injury, fecal short-chain fatty acids butyrate and propionate levels were lower in intestinal

41 Furthermore, short-chain fatty acids butyrate and propionate protect against hepatic IR injur

42 tin, and the short-chain fatty acids (SCFAs) butyrate and propionate were determined in children aged

43 Like butyrate and propionate, the prototypical hydroxyamic ac

44 at the same time increased the production of butyrate and propionate.

45 Propionate, butyrate and pyruvate also reduced contractions with sim

46 d by differentiated colonocytes that consume butyrate and stimulate future studies on the interplay o

47 Predicted levels of butyrate and substrates involved in butyrate synthesis (

48 and the short-chain fatty acids acetate and butyrate and then alter transcription of colonization fa

49 These included seven taxa that produce butyrate and three taxa that degrade oxalate.

50 cal product norcarnitine as well as acetate, butyrate, and caproate.

51 rpolymerization of propylene oxide, glycidyl butyrate, and CO(2), catalyzed by a cobalt salen complex

52 Targeting the gut microbiome, butyrate, and its consequences may represent novel viabl

53 Important metabolites such as acetate, butyrate, and propionate are generated at relatively hig

54 chain fatty acids (SCFAs) including acetate, butyrate, and propionate on growth, morphogenesis, and G

55 of higher organic acids (e.g., lactate, iso-butyrate, and propionate), which was accompanied by incr

56 cells and SCFAs, more specifically acetate, butyrate, and propionate.

57 lt, treated DOCA-salt-BFM, treated DOCA-salt-butyrate, and treated DOCA-salt-acetate, for 5 weeks.

58 Furthermore, the influences of butyrate are lost in cells lacking HIF, thus linking but

59 s suggest that the sleep-inducing effects of butyrate are mediated by a sensory mechanism located in

60 ydrates (NDCs)] and the fermentation product butyrate are protective against colorectal cancer and ma

61 acids (SCFAs; e.g., acetate, propionate, and butyrate) are produced by microbial fermentation of fibe

62 fatty acids (SCFAs), acetate, propionate and butyrate, are bacterial metabolites that mediate the int

63 fatty acids (SCFAs), acetate, propionate and butyrate, are bacterial metabolites that mediate the int

64 ds (SCFAs), such as acetate, propionate, and butyrate, are produced in high amounts in the gastrointe

65 major SCFAs, such as acetate, propionate and butyrate, are significantly decreased in long-term activ

66 e study's findings suggest the importance of butyrate as a pivotal HM compound able to protect agains

67 ighlight the importance of SCFAs, especially butyrate as a promising therapeutic agent in allergic in

68 limus affects glucose metabolism through the butyrate-associated GLP-1 pathway in the gut, and oral s

69 ched microbiome formed iso-caproate from iso-butyrate at a rate of 44 +/- 6 mmol C L(-1) day(-1) duri

70 rted the synthesis of a novel poly(3-hydroxy butyrate)-b-poly(vinyl benzyl xanthate) block copolymer

71 main target of the beneficial effect of both butyrate-based compounds in reverting insulin resistance

72 ed methanogenic communities with propionate, butyrate, benzoate, acetate, formate and H2 from two dif

73 The Prot diet increased butyrate (beta: 0.05; 95% CI: 0.00, 0.09) compared with

74 physiological concentrations of beta-hydroxy butyrate (BHB), glucose, and iron that are similar to th

75 that encodes a composite inositol catabolism-butyrate biosynthesis pathway, the presence of which is

76 ctions important for H2 and CO2 homeostasis, butyrate biosynthesis, ATP-binding cassette (ABC) transp

77 Propionate and butyrate, but not acetate, inhibited IgE- and non-IgE-me

78 Butyrate, but not other SCFAs, induced SYNPO in epitheli

79 In contrast, in DSS-induced inflammation, butyrate-, but not HCO3 (-)-dependent Na(+) absorption i

80 nsduction system (TCS) directs a response to butyrate by identifying mutants in a genetic screen defe

81 ites produced by the gut microbiome, such as butyrate, can have complex effects on cellular physiolog

82 ed short-chain fatty acids, and particularly butyrate, can promote immune tolerance.

83 salt, yields the poly(propylene-co-glycidyl butyrate carbonate)s (PPGBC)s.

84 It was stated that "butyrate circulates at mM levels (as opposed to uM in co

85 sed to uM in colon)"; this should have read "butyrate circulates at uM levels (as opposed to mM in co

86 on error, the concentration scales given for butyrate circulates in the bloodstream and colon were in

87 rumen plant material to acetate, propionate, butyrate, CO2, and methane.

88 Pyruvate and butyrate competed for acetyl-CoA production, as evidence

89 concentration in HM, and to see whether the butyrate concentration detected in HM is able to modulat

90 HM butyrate concentration from 109 healthy women was assess

91 We aimed to define the butyrate concentration in HM, and to see whether the but

92 The median butyrate concentration in mature HM was 0.75 mM.

93 This butyrate concentration was responsible for the maximum m

94 resulted in a significant increase in fecal butyrate concentration.

95 in a separate model.Acetate, propionate, and butyrate concentrations decreased throughout the day (P

96 ionate production, a 39.1% increase in colon butyrate concentrations, and a reduction in the number o

97 fine the specific mechanism(s) through which butyrate contributes to these epithelial responses.

98 Microbiota function demonstrated reduced butyrate contributing taxa as potentially responsible fo

99 Fecal butyrate correlated with days free of intensive care at

100 Our work further suggests that butyrate could be broadly used as a tool to increase gro

101 rnative metabolic pathways in situ producing butyrate, cyclohexanecarboxylate and benzoate as catabol

102 e (decrease 5.7 +/- 7.8 vs 5.2 +/- 7.9), and butyrate (decrease 7.0 +/- 7.4 vs 10.2 +/- 8.5).

103 3-hydroxy butyrate dehydrogenase, 3-hydroxy butyrate dehydrogenase 2 (Bdh2), catalyzes a rate-limiti

104 An evolutionarily conserved 3-hydroxy butyrate dehydrogenase, 3-hydroxy butyrate dehydrogenase

105 Initial studies with butyrate demonstrated that this compound significantly i

106 inflammation activates NHE2, which mediates butyrate-dependent (but not HCO3 (-)-dependent) Na(+) ab

107 demonstrate that both HCO3 (-)-dependent and butyrate-dependent Na(+) absorption are inhibited by S32

108 on NHE3 mediates both HCO3 (-)-dependent and butyrate-dependent Na(+) absorption, whereas DSS-induced

109 subcutaneous or intraperitoneal injection of butyrate did not have any significant effect on sleep or

110 Dietary butyrate did not stimulate gut hormone secretion.

111 in the presence of the bacterial metabolite butyrate display enhanced antimicrobial activity.

112 Butyrate drove this monocyte to macrophage differentiati

113 l and structural plasticity induced by ethyl butyrate (EB) or carbon dioxide (CO(2)) closes within 48

114 on), as a result of acetate and subsequent n-butyrate elongation.

115 ECs), we discovered that SCFAs, particularly butyrate, enhanced IEC barrier formation, induced IL-10R

116 Inhibition of HDAC activity by sodium butyrate enhances recruitment of acetylated histone 3 to

117 al partial least squares (OPLS) associated a butyrate ester of pinobanksin with high activity against

118 e extracts, a release was observed for ethyl butyrate, ethyl 2-methylbutyrate, ethyl 3-methylbutyrate

119 es to a mixture of odorants, including ethyl butyrate, eugenol, and carvone, considerably increased t

120 e demonstrate that OAT7 is a very weak urate-butyrate exchanger.

121 equired for pathogen clearance and decreased butyrate expression.

122 Products of microbial fermentation including butyrate facilitate the generation of peripherally induc

123 ira and acetate (FDR-corrected P = 0.002) or butyrate (FDR-corrected P = 0.005).

124 c analysis to determine whether dysbiosis in butyrate fermentation could be identified in human infan

125 ; 6% of bacteria had an atypical pathway for butyrate formation and 33% of bacteria had an atypical o

126 The butyrate-G-protein-coupled receptor 43-GLP-1 pathway in

127 yrate-producing gut microbiota with elevated butyrate generation, as demonstrated by 16S rRNA sequenc

128 Accordingly, we discovered that although butyrate globally increases baseline expression of more

129 metabolic pathway network analysis for GABA, butyrate, glutamate, monoamines, monosaturated fatty aci

130 The pendant polar hydroxyl and non-polar butyrate groups between amides allow controlled programm

131 also reduced NF-kappaB activity in the order butyrate>propionate>>acetate with IC(5)(0) of 51, 223, a

132 t observed with decitabine and pomalidomide; butyrate had an intermediate effect whereas tranylcyprom

133 igh in either acetate (HA), propionate (HP), butyrate (HB) or placebo (PLA) were rectally administere

134 lls with decitabine (demethylating agent) or butyrate (histone deacetylase inhibitor) restored hOCT1

135 e three main SCFAs (acetate, propionate, and butyrate) improved renal dysfunction caused by injury.

136 The reduced butyrate in CD326(+) intestinal epithelial cells (IECs)

137 ort-chain fatty acids (SCFAs) propionate and butyrate in day 100 plasma samples from patients who dev

138 are utilized by the host and propionate and butyrate in particular exert a range of health-promoting

139 rt-chain fatty acids propionate, acetate and butyrate in the cecum were significantly reduced in 13-w

140 subsets of ISGs depending on the presence of butyrate in the cell environment, and overall, they iden

141 abundant presence of HDAC inhibitors such as butyrate in the intestine, we found that HDAC3 activity

142 microbiota and their products, specifically butyrate, in the regulated expression of SYNPO for intes

143 We found that butyrate increases cellular infection with viruses relev

144 Administration of butyrate induced antimicrobial activity in intestinal ma

145 Mechanistically, butyrate induced small intestinal IL-10 expression and d

146 ajor SCFAs, such as acetate, propionate, and butyrate, induced the disease.

147 Butyrate-induced antimicrobial activity was associated w

148 Sodium butyrate-induced differentiation of HT29 and Caco-2 cell

149 ency of cancer cells, and reduced the sodium butyrate-induced differentiation of HT29 cells.

150 We previously reported that sodium butyrate-induced differentiation of HT29 colon cancer ce

151 Transcriptome analyses revealed butyrate-induced downregulation of the tyrosine kinases

152 tion, and (2) the simultaneous inhibition of butyrate-induced Hsp25 by Wnt-5a which is necessary to a

153 rall, they identify a new mechanism by which butyrate influences virus infection of cells.IMPORTANCE

154 HDAC3-dependent proliferation and countered butyrate inhibition of colonic growth.

155 In the first 6 hours after the butyrate injection, NREMS increased by 70%.

156 cial conversion of hydrophobic p-nitrophenyl butyrate into yellow water-soluble p-nitrophenolate cata

157 Butyrate is a gut microbiota-derived metabolite able to

158 While butyrate is a known histone deacetylase inhibitor that a

159 fluences virus infection of cells.IMPORTANCE Butyrate is a lipid produced by intestinal bacteria.

160 Butyrate is a microbial metabolite with pleiotropic effe

161 Butyrate is a short-chain fatty acid produced by the int

162 Butyrate is an abundant metabolite produced by gut micro

163 ocol using HP [1-(13)C]pyruvate and [1-(13)C]butyrate is used to measure carbohydrate versus fatty ac

164 f short-chain fatty acids and in particular, butyrate, is necessary for the ability of PTH to increas

165 Microbiota-derived bioproducts butyrate, lactate, and polysaccharide A improved barrier

166 h the oral and intraportal administration of butyrate led to a significant drop in body temperature.

167 Similarly, intraportal injection of butyrate led to prompt and robust increases in NREMS in

168 Microbiota depletion lowered butyrate levels, a metabolite responsible for gut-bone c

169 tion was accompanied by dysbiosis, decreased butyrate levels, and substantially elevated lactate leve

170 mouse intestinal lumen, leading to decreased butyrate levels, increased epithelial oxygenation, and a

171 supported by increased lactate and decreased butyrate levels.

172 t-chain fatty acids acetate, propionate, and butyrate, ligands that originate largely as fermentation

173 optimal colonization of avian hosts, senses butyrate likely by indirect means to alter transcription

174 asis, differentiated colonocytes metabolized butyrate likely preventing it from reaching proliferatin

175 C3 organic acids or dicarboxylic acids (e.g. butyrate, malonate and succinate).

176 hibitor 5-azacytidine and the HDAC inhibitor butyrate markedly reduced CSC abundance and increased th

177 We tested the hypothesis that butyrate may serve as a bacterial-derived sleep-promotin

178 Butyrate [median (IQR): 31 ng/mL (112-22 ng/mL) compared

179 wn increased GM2-synthase transcription, and butyrate-mediated activation of GM2-synthase mRNA expres

180 ):acetate-CoA-transferase, a major enzyme in butyrate metabolism (OR = 0.43 (0.19-0.97), P = 0.042).

181 e sought to determine the role of epithelial butyrate metabolism in establishing the austere oxygenat

182 are lost in cells lacking HIF, thus linking butyrate metabolism to stabilized HIF and barrier functi

183 r data suggest that (1) increased intestinal butyrate might represent a strategy to bolster host defe

184 Additionally, butyrate modulated gene expression and immune cells in t

185 In this study, we identified the C. jejuni butyrate-modulated regulon and discovered that the BumSR

186 ng mutants in a genetic screen defective for butyrate-modulated transcription.

187 Specifically, we show that sodium butyrate (NaB) and panobinostat (LBH589), two broad-spec

188 atment against ulcerative colitis and sodium butyrate (NaB), a short chain fatty acid (SCFA) normally

189 Sodium butyrate (NaBu), a form of short-chain fatty acid (SCFA)

190 tion of lactate-utilizing bacteria producing butyrate, namely Eubacterium and Anaerostipes species, s

191 inea pigs were used to assess the effects of butyrate on allergic airway contraction.

192 The effects of butyrate on enhancing induction of Cyp1b1/CYP1B1, AhR re

193 The effect of HM butyrate on tolerogenic mechanisms was assessed in in vi

194 fects of the SCFAs (acetate, propionate, and butyrate) on mast cell-mediated pathology and human mast

195 barrier in the pre-phase of arthritis using butyrate or a cannabinoid type 1 receptor agonist inhibi

196 for hepatic IR, exogenous administration of butyrate or propionate protected against hepatic IR inju

197 s of asthma with the measured level of fecal butyrate (OR = 0.28 (0.09-0.91), P = 0.034), bacterial t

198 (r(smax)) for both syntrophic propionate and butyrate oxidation.

199 ionate oxidation and a pH-mediated effect on butyrate oxidation.

200 s early pre-habilitation (ie, 3 days), stool butyrate per microbial biomass remained low and postoper

201 erivative dihydrohaemanthamine with acetate, butyrate, pivalate or hexanoate led to compounds that di

202 (2019) report that butyrate preconditioning of macrophages enhances their a

203 Oral gavage administration of tributyrin, a butyrate pro-drug, elicited an almost 50% increase in no

204 Together, these data highlight the role that butyrate produced by gut luminal microbiota plays in tri

205 Butyrate, produced by fermentation in the large intestin

206 Short-chain fatty acids (SCFAs), such as butyrate, produced through anaerobic microbial metabolis

207 crobial populations, including the main SCFA-butyrate producers in the colon, were not altered in the

208 risk ratio = 0.84[95% CI: 0.73 - 0.95]) and butyrate-producers (adjusted risk ratio = 0.82 [95% CI:

209 ; 95% confidence interval [CI], .73-.95) and butyrate-producers (aRR, 0.82; 95% CI, .67-.97).

210 the richness of obligate anaerobes and known butyrate-producers in all infants.

211 ociated with lower richness of anaerobes and butyrate-producers within 1 week after therapy.

212 ociated with lower richness of anaerobes and butyrate-producers within a week after therapy.

213 ated to the enriched OTUs, including several butyrate-producers, demonstrated that the strains caused

214 vironmental factors, of major propionate and butyrate producing bacteria are discussed in relation to

215 In addition, H. contortus-induced changes in butyrate producing bacteria could regulate mucosal infla

216 t 25(OH)D itself, are more likely to possess butyrate producing bacteria that are associated with bet

217 ples were Roseburia inulinivorans DSM 16841, butyrate producing bacterium SS3/4 and most of MGS enric

218 and lower relative abundance of Roseburia, a butyrate producing genus, and Bilophila, a bile acid met

219 tion (7DP), there was greater restoration of butyrate producing taxa and survival after surgery impro

220 -0.54, P = 0.002) and with the abundance of butyrate-producing bacteria (r = -0.52, P = 0.005).

221 el, with reduction in taxonomic abundance of butyrate-producing bacteria and decreased butyric acid c

222 vestigated the effects of well-characterized butyrate-producing bacteria Clostridium butyricum CGMCC0

223 We hypothesized that supplementation with butyrate-producing bacteria may exert beneficial effects

224 e abundant in HF diabetic mice and increased butyrate-producing bacteria.

225 ts with type 2 diabetes (T2D) have decreased butyrate-producing bacteria.

226 tective effect is linked to the expansion of butyrate-producing Bacteroidetes.

227 olonic microbiota and was not related to the butyrate-producing capacity in the faecal samples.

228 The butyrate-producing capacity of the intestinal microbiota

229 with 17 rationally selected strains of high butyrate-producing Clostridia also decreased GVHD.

230 t streptomycin treatment depleted commensal, butyrate-producing Clostridia from the mouse intestinal

231 ion through the same mechanism: depletion of butyrate-producing Clostridia to elevate epithelial oxyg

232 Depletion of butyrate-producing Clostridia, either through oral antib

233 ice and patients, suppressing the beneficial butyrate-producing Clostridium butyricum.

234 ded with the increase in bacteria related to butyrate-producing Coprococcus eutactus (r = -0.59, P =

235 Here, we show that the prominent butyrate-producing Firmicute Roseburia intestinalis expr

236 evotellaceae and Ruminococcaceae and several butyrate-producing genera abundances with APOE genotypes

237 and Faecalibacterium species, both renowned butyrate-producing gut commensals.

238 dontitis rats harbored a higher abundance of butyrate-producing gut microbiota with elevated butyrate

239 We found that the depletion of butyrate-producing microbes by antibiotic treatment redu

240 Eubacterium rectale, an important butyrate-producing organism in the gut, consumes a limit

241 microbiome shifts in T2D with a depletion of butyrate-producing taxa.

242 91), P = 0.034), bacterial taxa that predict butyrate production (OR = 0.38 (0.17-0.84), P = 0.017) a

243 There was a thermal environment effect on butyrate production (P < 0.01) that was not associated w

244 We sought to determine whether bacterial butyrate production in the gut during early infancy is p

245 ost mucosal immune cells and enterocytes via butyrate production, or contribute to synergism within a

246 g key enzymes for carbohydrate breakdown and butyrate production.

247 a novel mechanism by which microbial-derived butyrate promotes barrier through IL-10RA-dependent repr

248 lls, and the short chain fatty acids (SCFAs) butyrate, propionate and acetate also induce similar pro

249 retion of short-chain fatty acids (including butyrate, propionate, and acetate) were observed in the

250 etry revealed higher faecal SCFAs, including butyrate, propionate, valerate, isovalerate, and hexanoa

251 ysis of CSCs treated with 5-azacytidine plus butyrate provided evidence that inhibition of chromatin

252 ay in the gut, and oral supplementation with butyrate provides new insights for the prevention and tr

253 electron acceptor, acetate, propionate, and butyrate readily elongated with ethanol, whereas an adap

254 Epigenome analyses indicated that butyrate redistributed global histone acetylation in hum

255 O in the mouse colon, which was rescued with butyrate repletion.

256 ly correlates with IEC barrier formation and butyrate represses permeability-promoting claudin-2 tigh

257 Here, we newly show that butyrate reprograms the innate antiviral immune response

258 TPA-inducible sequence 11b/butyrate response factor 1 (TIS11b/BRF1) belongs to the

259 Butyrate restoration improved IEC junctional integrity,

260 ile reestablishment of physiologic levels of butyrate restored PTH-induced anabolism.

261 .g., Clostridia) and associated decreases in butyrate result in increased tissue oxygen and increased

262 type I IFNs are repressed in the presence of butyrate, resulting in increased virus infection and rep

263 In in vivo loop studies HCO3 (-)-Ringer and butyrate-Ringer exhibit similar rates of water absorptio

264 Lumen butyrate-Ringer incubation activated NHE3-mediated Na(+)

265 whereas in DSS-induced inflammation luminal butyrate-Ringer reversed water secretion observed with H

266 nhibitors (HDACIs) trichostatin A and sodium butyrate (SB) ameliorate mitochondrial function in cells

267 ar, the histone deacetylase inhibitor sodium butyrate (SB) may indirectly (through reduced hypoxia-in

268 Our data suggest that the metabolite butyrate, secreted by the gut microbiome, underlies some

269 Initial studies revealed that butyrate selectively promotes epithelial barrier functio

270 Our findings suggest that butyrate sensing by this system is vital for C. jejuni c

271 Hepatoportal butyrate-sensitive mechanisms may play a role in sleep m

272 ithelial signaling through the intracellular butyrate sensor peroxisome proliferator-activated recept

273 Pretreatment with butyrate significantly reduced allergic response in thre

274 Data from human cell models show that butyrate stimulated human beta defensin-3, mucus compone

275 effects were mimicked by acetate, but not by butyrate supplementation.

276 IF expression, both of which are restored by butyrate supplementation.

277 Mechanistically, butyrate suppresses levels of specific antiviral IFN-sti

278 Butyrate synergistically enhanced AhR ligand-induced Cyp

279 evels of butyrate and substrates involved in butyrate synthesis (ethanol or acetaldehyde) were signif

280 erial metabolites, like hydrogen sulfide and butyrate, the extent of their oxidation in colonocytes a

281 Following lytic reactivation by sodium butyrate, the levels of the approximately 23- to 24-kDa

282 Exposure of stem/progenitor cells in vivo to butyrate through either mucosal injury or application to

283 se whose activity is influenced by exogenous butyrate to control the level of endogenous phosphorylat

284 Butyrate treatment inhibited allergen-induced histamine

285 adecanoylphorbol-13-acetate (TPA) and sodium butyrate treatment, in EBV-infected epithelial cells by

286 om mouse model show that in basal condition, butyrate up-regulated the expression of several biomarke

287 Butyrate uptake was unaffected by fasting, as indicated

288 colonic-administered acetate, propionate and butyrate was 36%, 9% and 2%, respectively.

289 Circulating butyrate was also negatively correlated with distal pain

290 riven increase in gut production of the SCFA butyrate was associated with improved insulin response a

291 The permissive activity of butyrate was mediated by GPR43 signaling in dendritic ce

292 Butyrate was required for PTH to increase the number of

293 Children with the highest levels of butyrate were also less likely to have a reported diagno

294 s of (13) C-labelled acetate, propionate and butyrate were introduced in the colon of 12 healthy subj

295 utyrate and longer-chained fatty acids above butyrate were not elongated.

296 Alterations in the amount of only one SCFA, butyrate, were observed only in the intestinal tissue.

297 Furthermore, oral supplementation with butyrate, whether for remedy or prevention, significantl

298 to generate short-chain fatty acids such as butyrate, which has anti-inflammatory effects.

299 rticles promote release of bacterial-derived butyrate, while F. nucleatum and CRC cells are eliminate

300 sterol, and blood pressure; and increases in butyrate with increases in insulin and glucose, and decr